Immunotech Biopharm seeks nod for HK IPO

By Jonathan Breen
09 Mar 2020

China’s Immunotech Biopharm has applied for listing approval in Hong Kong, aiming to raise more than $100m from its IPO, according to a source familiar with the matter.

Before it can finalise a timetable for the deal, Immunotech and its IPO sponsors, CCB International and Guosen Securities, must meet the HKEX listing committee. That could be a challenge, however, as meetings have been pushed back and finding dates has become increasingly unpredictable as the outbreak of ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial